Ohio Clinical Trials Report — July 2026

Ohio residents considering a clinical trial should act quickly if they find a suitable study: 168 recruiting trials are expected to close within the next 90 days. Of these, 23 accept healthy volunteers. The most time-sensitive opportunities involve ovarian cancer, breast cancer, prostate cancer, ischemic stroke, liver cancer, and endometrial cancer.

At the same time, Ohio opened 71 new trials in July, up from 64 in May. The state now has 3,131 recruiting trials across 154 cities and 1,715 research sites. People who need treatment options, as well as healthy adults interested in research, should begin screening now because eligibility checks and appointments can take time.

Closing enrollment is concentrated in cancer and stroke research

Cancer patients have the largest group of closing-soon opportunities. Ovarian cancer and breast cancer each account for 5 trials nearing their projected closing dates. Prostate cancer follows with 4, while liver cancer, endometrial cancer, and advanced solid tumor studies each have 3. Some trials address more specific diagnoses, including HER2-negative breast cancer.

• Ovarian cancer — 5 closing-soon trials
• Breast cancer — 5
• Prostate cancer — 4
• Ischemic stroke, liver cancer, endometrial cancer, and advanced solid tumor — 3 each
• HER2-negative breast cancer, diabetic foot ulcer, and intracerebral hemorrhage — 2 each

The 23 closing trials that accept healthy volunteers create a narrower window for people without a diagnosed condition. Healthy adults can also consider the broader statewide pool: 281 recruiting trials in Ohio currently accept healthy volunteers. Because projected closing dates can change, potential participants should verify enrollment status with the study team rather than waiting until the final weeks.

July brings major Phase 2 and Phase 3 studies

Ohio’s new-trial activity spans drug, device, behavioral, procedure, and other research. Drug studies led with 26 openings, followed by device trials and behavioral studies with 14 each. The month’s new conditions included anxiety, several stages of breast cancer, relapsed or refractory multiple myeloma, chronic lymphocytic leukemia, chronic nausea, and acute sinusitis.

• Anxiety — 2 new trials
• Anatomic stage I, II, and III breast cancer — 2 each
• Relapsed or refractory multiple myeloma — 2
• Chronic lymphocytic leukemia and chronic nausea — 2 each
• Anatomic stage 0 breast cancer, amitriptyline, and acute sinusitis — 1 each

Several large, late-stage studies stand out for their sponsors and potential reach:

• NCT07684235 — Amgen’s Phase 3 MARITIME-1-EXTENSION study of maridebart cafraglutide for people with obesity or overweight. The extension plans to enroll 3,200 participants and will evaluate long-term efficacy, safety, and tolerability.
• NCT07697456 — AbbVie’s Phase 2 study of advanced therapies for adults with moderately to severely active Crohn’s disease or ulcerative colitis, with planned enrollment of 2,000.
• NCT07720284 — AstraZeneca’s Phase 3 study comparing Dato-DXd plus rilvegostomig with standard care for adults with high-risk muscle-invasive urothelial cancer after surgery. The study plans to enroll 915 participants.
• NCT07680790 — Bristol-Myers Squibb’s Phase 3 IZABRIGHT-Lung02 study for previously untreated, locally advanced or metastatic EGFR-mutant non-small cell lung cancer, with 850 planned participants.
• NCT07735637 — AstraZeneca’s Phase 3 DURGA-6 study comparing AZD0120 with autologous stem-cell transplant in transplant-eligible people newly diagnosed with multiple myeloma. Planned enrollment is 750.

Families may also see new pediatric opportunities. NCT07730814 and NCT07732699 are Phase 4 studies sponsored by Nader Shaikh that compare available treatments for acute ear infections and acute sinusitis in children. Each plans to enroll 1,100 participants and examines whether antibiotics help children recover more quickly.

Ohio State University Comprehensive Cancer Center is sponsoring NCT07702435, a study of oral nicotine product messaging among young adults. With 607 planned participants, it examines how different messages communicate the risks of oral nicotine pouches. The study reflects Ohio’s mix of prevention, behavioral, and public-health research beyond traditional drug development.

Columbus and Cleveland lead a statewide research network

New trial openings are concentrated in Ohio’s largest academic and medical centers. Columbus led decisively with 37 new trials, followed by Cleveland with 19 and Cincinnati with 11. Dayton added 3, while Mason, Mayfield Heights, Akron, Sandusky, Brunswick, and Canfield each recorded 1.

• Columbus — 37 new trials
• Cleveland — 19
• Cincinnati — 11
• Dayton — 3
• Mason, Mayfield Heights, Akron, Sandusky, Brunswick, and Canfield — 1 each

The pattern shows a strong metropolitan concentration, particularly around Columbus, Cleveland, and Cincinnati, but opportunities extend into communities across the state. Ohio State University opened 19 new trials, and Ohio State University Comprehensive Cancer Center added 5. Case Comprehensive Cancer Center and The Cleveland Clinic each sponsored 3 new studies. Children’s Hospital Medical Center, Cincinnati, and Nader Shaikh each sponsored 2, as did AbbVie.

Healthy volunteers, children, and older adults have new options

Of July’s 71 new trials, 11 accept healthy volunteers. These studies may involve behavioral research, prevention, messaging, or other questions that do not require a diagnosed illness. Healthy adults should review participation requirements carefully, including age ranges, visit schedules, compensation details if offered, and travel expectations.

Children are included in 15 new trials, creating opportunities for families seeking research involving pediatric infections and other conditions. 7 studies are female-only, while no new trials are male-only. Older adults appear in 59 new-trial eligibility criteria, making age-related research an important part of Ohio’s July pipeline.

Academic and nonprofit research remains the dominant force behind the month’s openings: 50 new trials are classified as “other,” compared with 18 industry-sponsored studies, 2 federal studies, and 1 NIH study. The mix of university-led investigations and major-sponsor Phase 2 and Phase 3 programs gives Ohio participants options ranging from local behavioral studies to large international drug trials.

With 71 new studies opening and 168 approaching closure, Ohio’s trial landscape will continue to shift through late summer. Patients with cancer, inflammatory bowel disease, multiple myeloma, lung cancer, or stroke-related conditions—and healthy adults near major research centers—should check newly opened and closing-soon studies now, before available enrollment windows narrow further.